PFE Volume Alert - PFE 30.12 Pfizer Inc $PFE Hit a high of 30.11 Currently 11:15 Last price 30.12 +0.20 +0.67% With a day low of 29.81 and a current volume of 5,992,530.
PFE Pfizer Inc Recent Headline News
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - 19 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.61 (-0.05), CRIS: 1.33 (+0.03), IMMU: 3.64 (+0.03), PCYC: 133.34 (-0.15), ONCY: 0.81 (+0.11), PFE: 30.23 (+0.31), LLY: 67.86 (+1.26), BMY: 58.59 (+0.27), GSK: 45.25 (+0.34), JNJ: 108.53 (+0.33), SNTA: 3.09 (-0.05), NVS: 92.56 (+0.80), XLRN: 31.86 (+1.67), ARRY: 3.91 (+0.03), CELGZ: 3.17 (-0.07), EXEL: 1.77 (+0.03)
Early Glance: Pharmaceuticals companies
AP - 1 hr 39 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.53 (+0.33), BAX: 70.58 (-0.03), PFE: 30.23 (+0.31), BMY: 58.58 (+0.26)
Amy Schulman Joins The Board Of Directors Of Blue Buffalo
PR Newswire - 2 hrs 34 mins ago
Blue Buffalo, the leading natural pet food company, announced today that Amy Schulman joined its Board of Directors. Ms. Schulman is currently the CEO of Arsia Therapeutics Inc., a Venture Partner at Polaris Ventures, and a Senior Lecturer at the Harvard Business School. Until recently, she was the Executive Vice President and General Counsel of Pfizer Inc., as well as the Business Unit Lead of Pfizer's Consumer Healthcare business.
PFE: 30.23 (+0.31)
3 Healthcare Stocks With Unbeatable Dividends
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 9:42AM CST
Large pharmaceutical companies are often known for their generous dividends. Let's check in on three such income generators -- GlaxoSmithKline , AstraZeneca , and Pfizer -- to see if their businesses can back up their yields. Source:...
PFE: 30.23 (+0.31), AZN: 73.26 (+0.38), GSK: 45.25 (+0.34)
Final Glance: Pharmaceuticals companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.53 (+0.33), BAX: 70.58 (-0.03), PFE: 30.23 (+0.31), BMY: 58.58 (+0.26)
Midday Glance: Pharmaceuticals companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.53 (+0.33), BAX: 70.58 (-0.03), PFE: 30.23 (+0.31), BMY: 58.58 (+0.26)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 201.52 (+2.94), PFE: 30.23 (+0.31), MRK: 58.67 (-0.67), AZN: 73.26 (+0.38), TEVA: 58.20 (+0.50), ITCI: 14.92 (-0.34), ABBV: 63.73 (+2.23), BMY: 58.58 (+0.26), OMER: 17.08 (-0.29)
Will Pfizer Sweeten Its Bid For AstraZeneca?
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
Now that the allure of tax inversion deals for U.S. companies has been damped down, Wall Street is wondering if Pfizer (PFE) will sweeten its takeover bid for AstraZeneca (AZN). The new rules "almost entirely remove the benefits," AstraZeneca CEO...
AZN: 73.26 (+0.38), PFE: 30.23 (+0.31)
Move Over Federal Reserve, There's a New Central Bank in Town
at The Street - Thu Nov 06, 1:35PM CST
The CNBC "Fast Money" trading panel says the stock market can go higher thanks to lower gasoline prices, improved earnings and the European Central Bank.
WFM: 47.31 (+0.50), TSLA: 242.39 (+2.19), VRX: 127.43 (+1.32), KR: 58.38 (+0.58), UN: 38.95 (+0.42), UTX: 108.91 (-0.17), PFE: 30.23 (+0.31), HAL: 53.57 (-0.29), TAP: 76.47 (-0.71), KORS: 69.53 (-0.42), TLT: 119.08 (-0.67), PEP: 96.89 (+0.09), DFS: 66.04 (+0.01), COH: 33.86 (+0.20), SPY: 203.85 (+0.51), QQQ: 101.94 (+0.34), QCOM: 69.23 (-0.03), DIA: 175.86 (+0.28), COST: 137.45 (-0.26), IWM: 116.75 (+0.04), MSFT: 49.06 (+0.38), CBS: 52.28 (+0.97)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 108.29 (+1.84), PFE: 30.23 (+0.31), LH: 100.71 (+0.19), ABBV: 63.73 (+2.23), CVD: 100.69 (+0.17)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 16.13 (+0.63), PFE: 30.23 (+0.31), AMGN: 162.55 (+2.30), AXN: 0.27 (-0.01), SRNE: 4.80 (+0.15), NKTR: 13.75 (+0.40), EGLT: 6.65 (-0.14), AZN: 73.26 (+0.38), VBAY: ()
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.23 (+0.31), INCY: 70.12 (+0.80), ONTX: 4.82 (+0.04), BMY: 58.59 (+0.27), GSK: 45.25 (+0.34), STML: 14.46 (-0.16), SNTA: 3.09 (-0.05), KBIO: 1.95 (+0.15), BPTH: 2.89 (-0.08), CELGZ: 3.17 (-0.07), NVS: 92.56 (+0.80)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.28 (-0.04), PFE: 30.23 (+0.31), AZN: 73.26 (+0.38), TTHI: 6.43 (-0.01), TEVA: 58.20 (+0.50), ITCI: 14.92 (-0.34), LLY: 67.86 (+1.26), OMER: 17.08 (-0.29)
Monotype Gets Its Font Tech Deeper Into Advertising
at Investor's Business Daily - Wed Nov 05, 5:26PM CST
Monotype Imaging Holdings (TYPE), a leading provider of typefaces and typeface technology, has been on a mission to beauty websites with new and better-rendered fonts. Now the Woburn, Mass.-based company is looking to make digital advertising more...
EBAY: 53.83 (+0.32), PFE: 30.24 (+0.32), CVS: 88.95 (+0.57), COST: 137.44 (-0.27), ADBE: 71.78 (+0.18), TYPE: 28.23 (-0.01)
Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference
Business Wire - Wed Nov 05, 10:00AM CST
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business, at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 8:00 a.m. Mountain Standard Time.
PFE: 30.24 (+0.32)
Why Bristol-Myers Squibb Co. Leaped 15% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 7:46AM CST
BMY data by YCharts What: Shares of big pharma giant Bristol-Myers Squibb shot higher by 15% in October, according to data from S&P Capital IQ , after the company reported better than expected third-quarter earnings results and...
PFE: 30.24 (+0.32), AZN: 73.26 (+0.38), BMY: 58.59 (+0.27)
PFE Pfizer Inc Recent Headline News
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - 19 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.61 (-0.05), CRIS: 1.33 (+0.03), IMMU: 3.64 (+0.03), PCYC: 133.34 (-0.15), ONCY: 0.81 (+0.11), PFE: 30.23 (+0.31), LLY: 67.86 (+1.26), BMY: 58.59 (+0.27), GSK: 45.25 (+0.34), JNJ: 108.53 (+0.33), SNTA: 3.09 (-0.05), NVS: 92.56 (+0.80), XLRN: 31.86 (+1.67), ARRY: 3.91 (+0.03), CELGZ: 3.17 (-0.07), EXEL: 1.77 (+0.03)
Early Glance: Pharmaceuticals companies
AP - 1 hr 39 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.53 (+0.33), BAX: 70.58 (-0.03), PFE: 30.23 (+0.31), BMY: 58.58 (+0.26)
Amy Schulman Joins The Board Of Directors Of Blue Buffalo
PR Newswire - 2 hrs 34 mins ago
Blue Buffalo, the leading natural pet food company, announced today that Amy Schulman joined its Board of Directors. Ms. Schulman is currently the CEO of Arsia Therapeutics Inc., a Venture Partner at Polaris Ventures, and a Senior Lecturer at the Harvard Business School. Until recently, she was the Executive Vice President and General Counsel of Pfizer Inc., as well as the Business Unit Lead of Pfizer's Consumer Healthcare business.
PFE: 30.23 (+0.31)
3 Healthcare Stocks With Unbeatable Dividends
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 9:42AM CST
Large pharmaceutical companies are often known for their generous dividends. Let's check in on three such income generators -- GlaxoSmithKline , AstraZeneca , and Pfizer -- to see if their businesses can back up their yields. Source:...
PFE: 30.23 (+0.31), AZN: 73.26 (+0.38), GSK: 45.25 (+0.34)
Final Glance: Pharmaceuticals companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.53 (+0.33), BAX: 70.58 (-0.03), PFE: 30.23 (+0.31), BMY: 58.58 (+0.26)
Midday Glance: Pharmaceuticals companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.53 (+0.33), BAX: 70.58 (-0.03), PFE: 30.23 (+0.31), BMY: 58.58 (+0.26)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 201.52 (+2.94), PFE: 30.23 (+0.31), MRK: 58.67 (-0.67), AZN: 73.26 (+0.38), TEVA: 58.20 (+0.50), ITCI: 14.92 (-0.34), ABBV: 63.73 (+2.23), BMY: 58.58 (+0.26), OMER: 17.08 (-0.29)
Will Pfizer Sweeten Its Bid For AstraZeneca?
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
Now that the allure of tax inversion deals for U.S. companies has been damped down, Wall Street is wondering if Pfizer (PFE) will sweeten its takeover bid for AstraZeneca (AZN). The new rules "almost entirely remove the benefits," AstraZeneca CEO...
AZN: 73.26 (+0.38), PFE: 30.23 (+0.31)
Move Over Federal Reserve, There's a New Central Bank in Town
at The Street - Thu Nov 06, 1:35PM CST
The CNBC "Fast Money" trading panel says the stock market can go higher thanks to lower gasoline prices, improved earnings and the European Central Bank.
WFM: 47.31 (+0.50), TSLA: 242.39 (+2.19), VRX: 127.43 (+1.32), KR: 58.38 (+0.58), UN: 38.95 (+0.42), UTX: 108.91 (-0.17), PFE: 30.23 (+0.31), HAL: 53.57 (-0.29), TAP: 76.47 (-0.71), KORS: 69.53 (-0.42), TLT: 119.08 (-0.67), PEP: 96.89 (+0.09), DFS: 66.04 (+0.01), COH: 33.86 (+0.20), SPY: 203.85 (+0.51), QQQ: 101.94 (+0.34), QCOM: 69.23 (-0.03), DIA: 175.86 (+0.28), COST: 137.45 (-0.26), IWM: 116.75 (+0.04), MSFT: 49.06 (+0.38), CBS: 52.28 (+0.97)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 108.29 (+1.84), PFE: 30.23 (+0.31), LH: 100.71 (+0.19), ABBV: 63.73 (+2.23), CVD: 100.69 (+0.17)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 16.13 (+0.63), PFE: 30.23 (+0.31), AMGN: 162.55 (+2.30), AXN: 0.27 (-0.01), SRNE: 4.80 (+0.15), NKTR: 13.75 (+0.40), EGLT: 6.65 (-0.14), AZN: 73.26 (+0.38), VBAY: ()
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.23 (+0.31), INCY: 70.12 (+0.80), ONTX: 4.82 (+0.04), BMY: 58.59 (+0.27), GSK: 45.25 (+0.34), STML: 14.46 (-0.16), SNTA: 3.09 (-0.05), KBIO: 1.95 (+0.15), BPTH: 2.89 (-0.08), CELGZ: 3.17 (-0.07), NVS: 92.56 (+0.80)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.28 (-0.04), PFE: 30.23 (+0.31), AZN: 73.26 (+0.38), TTHI: 6.43 (-0.01), TEVA: 58.20 (+0.50), ITCI: 14.92 (-0.34), LLY: 67.86 (+1.26), OMER: 17.08 (-0.29)
Monotype Gets Its Font Tech Deeper Into Advertising
at Investor's Business Daily - Wed Nov 05, 5:26PM CST
Monotype Imaging Holdings (TYPE), a leading provider of typefaces and typeface technology, has been on a mission to beauty websites with new and better-rendered fonts. Now the Woburn, Mass.-based company is looking to make digital advertising more...
EBAY: 53.83 (+0.32), PFE: 30.24 (+0.32), CVS: 88.95 (+0.57), COST: 137.44 (-0.27), ADBE: 71.78 (+0.18), TYPE: 28.23 (-0.01)
Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference
Business Wire - Wed Nov 05, 10:00AM CST
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business, at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 8:00 a.m. Mountain Standard Time.
PFE: 30.24 (+0.32)
Why Bristol-Myers Squibb Co. Leaped 15% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 7:46AM CST
BMY data by YCharts What: Shares of big pharma giant Bristol-Myers Squibb shot higher by 15% in October, according to data from S&P Capital IQ , after the company reported better than expected third-quarter earnings results and...
PFE: 30.24 (+0.32), AZN: 73.26 (+0.38), BMY: 58.59 (+0.27)
